Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
- PMID: 28284917
- DOI: 10.1016/j.jhep.2017.02.032
Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
Comment on
-
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26. J Hepatol. 2017. PMID: 28131794 Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
